Answer
Nausea is listed as very common (at least 1 in 10) for Emtricitabine/Tenofovir Alafenamide Gilead, with 11% reported in treatment-naïve adults receiving emtricitabine/tenofovir alafenamide with elvitegravir/cobicistat as a fixed-dose combination through 144 weeks.
Sources for this answer
- Emtricitabine/Tenofovir Alafenamide Gilead 200 mg/10 mg film coated tabletsGilead Sciences Ltd · emc · SmPC §4.8 Undesirable effects · Version 25Document updated
Sources checked